RecruitingNCT03188874
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Studying Inherited acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Technische Universität Dresden
- Principal Investigator
- Christoph Röllig, Prof. Dr.Universitätsklinikum Carl Gustav Carus
- Enrollment
- 15000 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2030
Study locations (30)
- Klinikum Mittelbaden, Baden-Baden, Baden-Wurttemberg, Germany
- Universtitätsklinikum Heidelberg, Heidelberg, Baden-Wurttemberg, Germany
- Klinikum Mannheim GmbH, Mannheim, Baden-Wurttemberg, Germany
- Diakonie-Klinikum, Schwäbisch Hall, Baden-Wurttemberg, Germany
- Kliniken Sindelfingen-Böblingen gGmbH, Sindelfingen, Baden-Wurttemberg, Germany
- Robert-Bosch-Krankenhaus GmbH, Stuttgart, Baden-Wurttemberg, Germany
- Rems-Murr-Klinikum Winnenden, Winnenden, Baden-Wurttemberg, Germany
- Klinikum Augsburg, Augsburg, Bavaria, Germany
- Sozialstiftung Bamberg, Bamberg, Bavaria, Germany
- Klinikum Bayreuth GmbH, Bayreuth, Bavaria, Germany
- MVZ Klinikum Coburg GmbH, Coburg, Bavaria, Germany
- ONKO Medeor Onkologische Zentren, Donauwörth, Bavaria, Germany
- Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
- Klinikum Nürnberg, Nuremberg, Bavaria, Germany
- Universitätsklinikum Würzburg, Würzburg, Bavaria, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03188874 on ClinicalTrials.govOther trials for Inherited acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06782542Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyJustin Watts, MD
- RECRUITINGPHASE2NCT06557421De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding PatientsInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07130695Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and ConsolidationVirginia Commonwealth University
- RECRUITINGPHASE1NCT07320235Imetelstat Combinations in Relapsed AMLDouglas Tremblay
- RECRUITINGPHASE2NCT06904482Co-Transplant of an Unmodified Haplo-Identical Graft With Cord BloodCase Comprehensive Cancer Center
- RECRUITINGNCT07163728Leptin: A Marker for AML Chemo-SensitivityFujian Medical University Union Hospital
- RECRUITINGNANCT06697600A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their CaregiversUniversity of Rochester
- RECRUITINGPHASE2, PHASE3NCT06972641Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationRuijin Hospital